chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Face and eyes started itching; Face and eyes started itching; Injection site itched a little bit; This spontaneous case was reported by a consumer and describes the occurrence of EYE PRURITUS (Face and eyes started itching), PRURITUS (Face and eyes started itching) and VACCINATION SITE PRURITUS (Injection site itched a little bit) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 005C21A) for COVID-19 vaccination.     Concurrent medical conditions included Penicillin allergy. Concomitant products included MULTIVITAMINS [VITAMINS NOS] for an unknown indication.    On 02-Sep-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 02-Sep-2021, the patient experienced EYE PRURITUS (Face and eyes started itching), PRURITUS (Face and eyes started itching) and VACCINATION SITE PRURITUS (Injection site itched a little bit). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency. On 02-Sep-2021, EYE PRURITUS (Face and eyes started itching), PRURITUS (Face and eyes started itching) and VACCINATION SITE PRURITUS (Injection site itched a little bit) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient was on birth control medication as an concomitant medication.  Other treatment medication include steroid cream when patient went to ER room.  After 30 minute patient face and eyes started itching. Injection site also itched a little bit. One of the HCP in the vaccination site asked patient to open their mouth and could not see patient's tonsils.
Received a pneumovax23 shot mid to high RH deltoid at a pharmacy with both people seated. 16hrs later, severe pain limits the ability to lift RH arm above the shoulder. Accompanied by Fever (99.5-101.5) unresponsive to 500mg Tylenol.
Initial unsolicited report received from a nurse on 22-May-2018. This case involves an 11-year-old patient (gender not reported) who was vaccinated with first and second 0.5 ml dose of MENACTRA (batch number: U4817AA, expiry date: 30-Jun-2019, dose, dose in series, route and site of administration were not reported) via intramuscular route on an unknown dates. It was a case of actual medication error due to inappropriate age at vaccine administration. Patient was given the second dose of MENACTRA injection at 11 years old and 6 Months. Frequency: 1st dose was given at 11 yrs and 2 months of age second dose 11 yrs and 6 months. Route was IM via the left deltoid. It was unknown whether adverse event occurred or not. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error. Documents held by sender: none.
Patient received vaccine on November 18, 2002 and developed chickenpox on December 2, 2002. No known community exposure.
I got a severe headache the day after my 2nd shot that lasted for two week before I ended up in the hospital. They did find a blood clot in my head also. Lab CRYPTOCOCCUS ANTIGEN MD Apr 12, 2021 Lab VARICELLA ZOSTER IGM MD Apr 12, 2021 Lab LYME TOTAL MD Apr 12, 2021 Lab IGG CSF INDEX SER MD Apr 11, 2021 Lab SYPHILIS TOTAL ANTIBODY SCREEN MD Apr 11, 2021 Imaging IR LUMBAR PUNCTURE DIAGNOSTIC MD Apr 11, 2021 Lab PROTEIN CSF MD Apr 11, 2021 Lab GLUCOSE CSF MD Apr 11, 2021 The result is abnormalLab CELL COUNT W/ DIFFERENTIAL IF INDICATED CSF MD Apr 11, 2021 Lab SPINAL FLUID CULTURE MD Apr 11, 2021 Lab PROTEIN ELECTROPHORESIS, CSF AND SERUM MD Apr 11, 2021 Lab HSV PCR MD Apr 11, 2021 Lab ENTEROVIRUS,CEREBROSPINAL FLUID, PCR MD Apr 11, 2021 Lab IGG INDEX SYNTH CSF MD Apr 11, 2021 Lab OLIGOBANDS INTERPRETATION MD Apr 11, 2021 The result is abnormalLab RBC CT, TUBE 1, CSF MD Apr 11, 2021 The result is abnormalLab MANUAL DIFFERENTIAL CSF MD Apr 11, 2021 Lab PROTIME-INR MD Apr 11, 2021 The result is abnormalLab LIPID PANEL PA-C Apr 11, 2021 The result is abnormalLab COMPREHENSIVE METABOLIC PANEL PA-C Apr 11, 2021 Lab MAGNESIUM PA-C Apr 11, 2021 Lab PHOSPHORUS PA-C Apr 11, 2021 Lab CBC WITH DIFFERENTIAL PA-C Apr 11, 2021 Imaging MRI BRAIN WITH AND WITHOUT CONTRAST AGPCNP Apr 10, 2021 Imaging MRV BRAIN WITH AND WITHOUT CONTRAST AGPCNP Apr 10, 2021 Imaging CT ANGIO NECK WITH IV CONTRAST AGPCNP Apr 10, 2021 The result is abnormalLab LIPID PANEL MD Apr 10, 2021 The result is abnormalLab COMPREHENSIVE METABOLIC PANEL MD Apr 10, 2021 The result is abnormalLab CBC WITH DIFFERENTIAL PA-C Apr 10, 2021 Lab EXTRA TUBE, LAV PA-C Apr 10, 2021 The result is abnormalLab HEMOGLOBIN A1C PA-C Apr 10, 2021 Lab COVID-19 PCR MD Apr 10, 2021 Imaging CT HEAD WITHOUT IV CONTRAST MD Apr 10, 2021 Imaging CT ANGIO HEAD WITH IV CONTRAST MD Apr 10, 2021 The result is abnormalLab POC ISTAT CREA CARTRIDGE MD Apr 10, 2021
chills; felt feverish; whole body hurts; other vaccine same date product: Flu vaccine; other vaccine same date product: Flu vaccine; arm hurt from the covid shot; headache; nauseous; This is a spontaneous report from a contactable other hcp. A 29-year-old non-pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), dose 3 via an unspecified route of administration on 16Oct2021 (at the age of 29-years-old) as dose 3 (booster), single for COVID-19 immunisation and received flu vaccine (INFLUENZA, formulation: not reported), via an unspecified route of administration from 16Oct2021 (Batch/Lot number was not reported) to 16Oct2021, at single for an unspecified indication. The patient's medical history included thyroid disorder, may have a gluten allergy. Patient was not pregnant at the time of vaccination. Patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), dose 2 via an unspecified route of administration on unspecified date as dose 2, single and first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported), dose 1 via an unspecified route of administration on unspecified date as dose 1, single for COVID-19 immunisation. Patient had two other shots within the week, likely allergy medication. It was reported that patient received flu vaccine on same date (I believe in opposite arm) and had received a total of 4 shots that week with also blood drawn. Patient said their arm hurt from the covid shot more so than from the flu shot on an unspecified date on Oct2021. They said the flu vaccine was administered with more force (based on how the HCP(s) administered both). Unsure when this side effect started. On 17Oct2021, day after vaccine between 10:30 am and 12:00 pm started getting chills and felt feverish. Unsure how long this lasted. Took temperature but did not get follow-up on reading. Patient might had taken ibuprofen to mitigate, but unsure. Additionally, at one point during the day on 16Oct2021 (after vaccine) before noon, hit arm with the vein from which they drew blood and shouted, "My whole-body hurts". Patient complained that she had a headache that day and were nauseous the whole day on an unspecified date on Oct2021. Unsure the timeframe in which there was a headache issue was brought up between 7-8 pm, which implies headache during that approximate time at least. The patient underwent lab tests and procedures which included took temperature but did not get follow-up on reading on an unspecified date. Patient might take ibuprofen to mitigate fever and chill. Reporter assesses the case was non-serious. The outcome of the event was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Five days after the second COVID dose I experienced what I thought was motion disturbances similar to a head concussion (week long symptoms) I had six months ago. When I looked into what brain fog was with the vaccine it was very evident that was what was going on. I actually did not realize how bad it was until much later when it cleared. Difficulty focusing and having to repeat processing events that has never happened before. Difficulty sitting and following conversation after an hour need to get up and leave. Still some motion dizziness when turning head fast or downward such as putting on shoes.
* First dose of Pfizer/BioNTech LOT: EP7534 on 03/14/2021 at 06:15 PM 6 minutes after injection a reaction of dizziness, chills, and paleness.  03/15/2021: Intense soreness near injection site on upper left arm muscle.  * Second does of Pfizer/BioNTech LOT: EP7533 on 04/04/2021  Normal soreness near injection site on upper left arm muscle.  04/05/2021: Intense body ache.  04/17/21: At approximately 02:00 AM numb sensations covering entire left arm, left face and neck, and a phantom sensation of numbness near injection site. Left arm feels droopy with less energy compared to right arm.
COVID-19 infection - tested positive 9/8.  He was admitted to the hospital 9/8, currently in the ICU on maximal high flow nasal cannula settings with very tenuous respiratory status on the verge of being intubated
forehead/eye popped backup. It's mild; This case was reported by a consumer via interactive digital media and described the occurrence of eye disorder in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   In October 2022, the patient received Shingles vaccine. In October 2022, less than 2 weeks after receiving Shingles vaccine, the patient experienced eye disorder. On an unknown date, the outcome of the eye disorder was unknown.   It was unknown if the reporter considered the eye disorder to be related to Shingles vaccine.     Additional Information: GSK Receipt Date: 20-Oct-2022 Reporter's comment: This case was reported by a patient via interactive digital media. The patient just had his/her shot about 2 weeks ago and the place on his/her forehead/eye popped back up.  It was mild but wow. Additional supportive information: The follow-up could not be possible as no contact detail were available.
Persistent cough; Hoarseness; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 12Apr2021 at 19:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history was not reported. Concomitant medications included famotidine (MANUFACTURER UNKNOWN), fexofenadine hydrochloride (ALLEGRA) and unspecified vitamins; all taken for unknown indications from an unknown date and unknown if ongoing. The patient previously received zolmitriptan (ZOMIG) taken for unknown indication and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration in the left arm on 22Mar2021 at 19:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 15Apr2021 at 16:00, the patient experienced persistent cough and hoarseness. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had been tested for COVID-19. On 16Apr2021, the patient underwent nasal swab test for COVID-19 and the result was negative. Therapeutic measures were taken as a result of the events and included treatment with MUCINEX and TYLENOL. The clinical outcome of the events persistent cough and hoarseness were not resolved at the time of this report.  No follow-up attempts are required; information about lot/batch number cannot be obtained. No further information is expected.
103 degree fever, headache, nausea, chills. Couldn't sleep. Started around 8:30pm, lasted until ibuprofen was taken around 4am.
No adverse effects that I'm aware of.  About 4 months later I visited Doctor due to persistent cough.  Diagnosed with sinus infection and heavy nasal drip.  Prescribed  antibiotic and antihistimine nasal spray. I'm still using nasal spray 3 months later.
Flublok Quadrivalent was administered to 17 years old patient, No AE; Initial information was received on 07-Oct-2020 regarding an unsolicited valid non-serious case from a pharmacist.  This case was linked to the case 2020SA279466 (same reporter).  This case involves a 17-years-old patient (gender unknown) who received a 0.5 mL dose of suspect INFLUENZA QUADRIVALENT RECOMBINANT VACCINE [FLUBLOK QIV] (lot QFAA2047, expiry date-30-Jun-2021) via an unknown route in left upper arm for prophylactic vaccination on 06-Oct-2020 (product administered to patient of inappropriate age).  Medical history, concomitant therapy, medical treatments, vaccinations and family history were not provided.  This was a case of an actual medication error due to inappropriate age at vaccine administration (latency same day).  It was reported that, no other medications or vaccinations were administered at that visit.   At the time of report, no adverse event was reported.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holders compliance with the requirements set out in Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Administered only the diluent; Administered only the diluent; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate preparation of medication in a patient who received Herpes zoster (Shingrix) (batch number XX474, expiry date unknown) for prophylaxis.   On 3rd October 2022, the patient received Shingrix. On 3rd October 2022, unknown after receiving Shingrix, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.   Additional Information: GSK Receipt Date: 04-Oct-2022 Reporter's comment: The vaccine coordinator reported that a patient received a vial of Shingrix diluent without reconstitution with the antigen powder.  The reporter believed this happened on 3rd October 2022.  The reporter consented to follow up. Additional Supportive Information: The patient received a vial of Shingrix diluent without reconstitution with the antigen powder, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered.
I had a breakthrough case of COVID-19 confirmed by a home test on July 4, 2022.
Noticed an obvious change in menstrual cycle after the first vaccine. Menstrual flow has been longer and  extremely heavier since my period in April. Headaches and intrusive thoughts and mood swings have  increased during my period also
7-20-10 developed flu like symptoms-fever (100degrees) H.A., vomiting, nausea, chills, body aches-states felt better the next day. ER visit 7-25-10-4 hr stay-received fluids-nausea med (injectable) and BENADRYL. 7-26-10 was seen by MD office had blood work-given med for nausea. 7-28-10-seen by MD office-follow up visit. States since then has had HA's daily, aches-mostly in shoulder, nausea, and fatigue-all intermittently. Reports developed sore throat starting 8-6-10. 7-26-10 was diagnosed with Urinary Tract Infection treated with CIPRO. Patient did not tell me about the UTI-found out today from MD office.
fever over 101, bad headaches, chills, weakness and dizziness. These symptoms lasted throughout the night and all day on Sunday, August 8,2021.     On  Monday, Aug 9 ,I have had a low grade fever that has been slightly over 99 and a mild headache and some weakness.
Hospitalized;  COVID-19 positive (9.5.21);  fully vaccinated  Admission Date: 9/5/2021 Discharge Date: 9/8/2021 DISCHARGE DIAGNOSES: 1. COVID-19 infection 2. Urinary retention 3. History of multiple strokes 4. Dementia with behavioral disturbance 5. Chronic liver disease 6. Anemia 7. Benign essential hypertension DETAILS OF HOSPITAL STAY: HOSPITAL COURSE: Patient is a 69-year-old male who was brought to the ED after testing positive for COVID-19 at his long-term care facility.  Due to his positive COVID test, he was unable to status facility, so was sent to the emergency department for further evaluation.  He was hemodynamically stable in the emergency department with normal labs, but due to placement issues, he was admitted to the hospitalist service for further care. Upon admission, the patient was monitored on the general medical floor.  We discussed regenerate on therapy with his guardian, but never heard back from the guardian as to whether or not she wished to pursue this, so it was never given.  He remained hemodynamically stable, with normal labs throughout his inpatient stay.  He is to be discharged for continued isolation until he can return to his local skilled nursing facility.
Patient received .5mL of FLUZONE instead of .25mL recommended dose for 15 month old.
HYPOTENSION 8/3/2022 &  8/8/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
28 weeks pregnant received my DTAP vaccine and started experience normal pain in my left arm at injection site. The following day it was red and a little bump had developed no pain. The second day it was red, even more swollen, and hot to the touch.
pt recvd vax;devel varicella rash;pt believe he was exposed to chicken pox 10 days a/ vax;
Initial shot had no pain on day one.  Sore Arm at injection site on day 2 & 3.  Feeling chills (feeling cold) in 75 degree weather with blankets on.  Night sweats and chills in bed.  Insomnia has lasted 3 weeks (sleep about 4-4.5 hours and CANNOT go back to sleep). ZERO History of insomnia before vaccine.
pt recvd vax; approx 4 hrs later pt devel chest pain, itching on her palms & soles of feet; pt had fever, nausea, & irritability; tx benadryl;
Patient states that she has tightening , chest tightening and swelling of the tongue. Patient was transported to the ER by ambulance.
On 01-06-2021 at 1:30am I had severe joint pain and as the day progressed I continued with pain. I also had a low grade fever of 99.5 F along with  muscle aches and headaches.  the next day I had extreme fatigue and developed a rash on my torso ( trunk). On 01-08-2021 the rash started to go away and my symptoms also began to resolve.
Patient completed two doses of Moderna COVID vaccines in June 2021. She presented at the ED c/o vomiting and diarrhea after taking Linzess on 12/24/21. She was found out of altered mental status and chest pain and admitted to the hospital. She also had low-grade fever and cough, and her COVID PCR was positive on 12/26/21. She has received IV steroids, but she was not required supplemental oxygen. She is going to be discharged home on 12/29/21.
101.4 fever, chills, body aches, migraine, extreme pain in injection site, lymph node swelling in lower armpit
patient plans to receive second dose 42 days after first dose; This spontaneous case was reported by a consumer and describes the occurrence of INTENTIONAL PRODUCT USE ISSUE (patient plans to receive second dose 42 days after first dose) in a 30-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 036A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INTENTIONAL PRODUCT USE ISSUE (patient plans to receive second dose 42 days after first dose). At the time of the report, INTENTIONAL PRODUCT USE ISSUE (patient plans to receive second dose 42 days after first dose) had resolved.            No relevant concomitant medications were reported.  Treatment information was not provided.
tested positive greater than 14 days post fully vaccinated tested positive greater than 14 days post fully vaccinated
Mother reports rash over daughter's entire body on 6-12-08 at 2:30 p.m. No breathing problems, fever. Instructed to administer Children's Benadryl and if symptoms persist then Dr. Appt
Temperature of 102.2 degrees / recurring high temperatures Vomiting Muscle aches / pain Tightness in neck muscles Lethargy
flare up of shingles; disease recurrence; This initial case was missing the following minimum criteria: no adverse event. Upon receipt of follow up information on 30Jan2021, this case now contains all required information to be considered valid.   This is a spontaneous report from a contactable consumer and nurse based on information received by Pfizer from   A 58 years old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection) on 18Jan2021 at single dose via an unspecified route of administration for COVID-19 immunization. Relevant medical history included ongoing psoriatic arthritis and shingles. Previous therapy included VIOXX and methotrexate, both for psoriatic arthritis. Concomitant medications included etanercept (ENBREL) for psoriatic arthritis. On 20Jan2021 two days later after received the vaccine the patient had a flare up of shingles. At the time of the reporting event outcome was unknown.    No follow-up attempts are possible, information about batch number cannot be obtained
Swelling of the face, and throat, difficulty breathing, fast heartbeat, dizziness, weakness, lethargic, coughing, wheezing.
This case was reported by a consumer and described the occurrence of injection site swelling in a elderly female patient who received Influenza vaccine. Previously administered products included influenza vaccine (swelling, pain, warmth and redness at the injection site dose 1). On an unknown date, the patient received the 2nd dose of Influenza vaccine. On an unknown date, unknown after receiving Influenza vaccine, the patient experienced injection site swelling, injection site warmth, injection site erythema, injection site pain, off label use and wrong injection technique. On an unknown date, the outcome of the injection site swelling, injection site warmth, injection site erythema, injection site pain, off label use and wrong injection technique were unknown. It was unknown if the reporter considered the injection site swelling, injection site warmth, injection site erythema and injection site pain to be related to the Influenza vaccine. Additional information: The doctor divided this second flu shot into 1/5th of the actual dose so he could try and mitigate any reactions to the shot itself. However, the same events occurred with this reduced flu shot dose. This case is linked with cases US2015057042 and US2015GSK061625 as same patient.
Received mammogram on 3/1/21 that came back as abnormal on right side. Repeated mammogram and got ultrasound on 3/12/21 that confirmed enlarged right lymph nodes. I was told it was most likely due to the Covid-19 vaccine being administered on that side, and that I needed to return in three months for follow up imaging.
Fever, chills, body aches, generalized weakness Narrative:  Other Relevant History:
acute pericarditis. improved with tx of NSAIDs. echo showed pericardial effusion. symptoms of acute chest pain, follow up echo pending